PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE k Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

Application Number	10/017,788	
Filing Date	December 13, 2001	
First Named Inventor	Nguyen, Quan , et. al.	
Art Unit	1645	
Examiner Name		
Attorney Docket Number	002558-064310US	

			U.S. PATENT D	OCUMENTS			
		Document Number			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Examiner Cite No.1	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			
	AA	US-					
	AB	US-			/.		
	AC	US-					
	AD	US-			/ m		
	AE	US-			구 구		
	AF	US-			- 		
	AG	US-			B B m		
	AH	US-			= 0		
	Al	US-			# 6 M		
	Ą	US-			5 8 		
	AK	US-					
	AL	US-					
	AM	US-			36 U		
	AN	US-			8		
	AO	US-					
	AP	U\$-					
	PA	U\$-					
	AR	US		·			
	AS	US-					
	AT	US-					

		FOREIGN PATENT DOCUMENTS									
	E	Cite No.1	Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines,				
_	Examiner Initials*		Country Code ³	Number ⁴	Kind Code [‡] (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T [©]		
Not	Considered	AU	EP				Hybritech Inc.				
NOT	CONS ALT	AV				11-29-1995	Behring Diagnostics Inc.				
	covilired	AW				02-13-1986	Shah				
Not	considered	AX				02-04-1993	Assay Research, Inc.				
		AY									
		AZ	1	. <u></u>							
		BA									
		68									

		<u> </u>				
Examiner Signature	Hany	Court	Date Considered	8/10/	04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.usplo.gg or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1432488 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute FIGATE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known				
Application Number	10/017,788			
Filing Date	December 13, 2001			
First Named Inventor	Nguyen, Quan , et. al.			
Art Unit	1645			
Examiner Name				
Attorney Docket Number	002558-064310US			

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.
GL	ВС	Brailly et al., Total Interleukin-6 in Plasma Measured by Immunoassay, Clin. Chem. 40, 116 (1994)
G	BD	Kakabakos et al., Multianalyte Immunoassay Based on Spatially Distinct Fluorescent Areas Quantified by Laser- Excited Solid-Phase Time-Resolved Fluorometry, Clin. Chem. 38, 338 (1992)
Ge	BE	Kricka, Selected Strategies for Improving Sensitivity and Reliability of Immunoassays, Clin. Chem. AN PREV 199497239111 [abstract only] (1994)
	BF	
	BG	TEC
	вн	FED
	81	TCE 9 2 6 VTER
	BJ	PECEIVED FEB 2 6 2003 TECH CENTER 1600/2900
	вк	2900 ED
	BL	
	вм	

Examiner Signature	Day Court	Date Considered	8/10/04	•

EXAMINER: Initial if reference considered) whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1432488 v1

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.